TIDMABC
RNS Number : 7630Z
ABCAM PLC
27 January 2022
27 January 2022
ABCAM PLC
Trading Update
Cambridge, UK : Abcam plc ("Abcam", "Company", "Group") (AIM:
ABC; Nasdaq: ABCM), a global leader in the supply of life science
research tools, today provides the following trading update ahead
of reporting its financial results in March:
The Group expects to report total revenues for the 12 months
ended 31 December 2021 of approximately GBP 315 million,
representing growth of over 22 % on a constant exchange rate (CER)
basis and 17 % on a reported basis (12 months to 31 December 2020:
GBP269.3 million). This figure includes a contribution of
approximately GBP2.5 million of incremental revenue(1) from
BioVision following the acquisition's completion on 27 October
2021.
Revenue growth continues to be driven by demand for the
Company's proprietary products, with in-house catalogue sales up
approximately 37% CER on an organic basis (43% including
BioVision), together with a continued recovery in global lab
activity. Whilst risks related to the pandemic remain - as
evidenced by the emergence of the Omicron variant in late 2021 -
data indicates that, while not yet returning to pre-covid levels,
overall lab activity continued to increase through 2021.
The Group has continued to build capabilities, invest in
innovation and implement its multi-year growth strategy throughout
the period. Overall, we anticipate adjusted operating profits will
be reported in line with the board's expectations for the period
and we remain on track to achieve our financial goals for the five
year plan ending in 2024.
Following the change in the Company's financial year end to 31
December, full results for the 18 month period ended 31 December
2021 will be released on 14 March 2022. In order to aid comparison,
pro forma information for the 12 month periods ended 31 December
2021 and 31 December 2020 will also be provided.
Alan Hirzel, CEO of Abcam commented:
"2021 was a year of significant innovation and growth in
proteomic tools and discovery. I thank our customers for trusting
Abcam as their preferred partner and our global colleagues for
their unwavering dedication to customer needs and aspirations.
Together, we are building a durable enterprise that is making a
difference in the pace and social impact of discovery. I am
confident in our progress toward our 2024 business goals and I look
forward to providing the full update in March."
(1) Incremental revenue excludes sales of BioVision products
through Abcam channels
This announcement contains inside information which is disclosed
in accordance with the Market Abuse Regulation.
Abcam plc
+ 44 (0) 1223 696 000
James Staveley, VP Investor Relations
Numis - Nominated Adviser & Joint Corporate Broker
+ 44 (0) 20 7260 1000
Garry Levin / Freddie Barnfield / Duncan Monteith
Morgan Stanley - Joint Corporate Broker
+ 44 (0) 207 425 8000
Tom Perry / Luka Kezic
FTI Consulting
+44 (0) 20 3727 1000
Ben Atwell / Lydia Jenkins
Note:
This trading update is based upon unaudited management accounts
and has been prepared solely to provide additional information on
trading to the shareholders of Abcam plc. All figures are
provisional and subject to further review. It should not be relied
on by any other party for other purposes.
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
antibodies, assays and other research tools to address important
targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health.
Abcam's worldwide customer base of approximately 750,000 life
science researchers uses Abcam's antibodies, reagents, biomarkers
and assays. By actively listening to and collaborating with these
researchers, the Company continuously advances its portfolio to
address their needs. A transparent programme of customer reviews
and datasheets, combined with an industry-leading validation
initiative, gives researchers increased confidence in their
results.
Founded in 1998 and headquartered in Cambridge, UK, the Company
has served customers in more than 130 countries. Abcam's ordinary
shares are listed on the London Stock Exchange (AIM: ABC) and its
American Depositary Shares (ADSs) trade on the Nasdaq Global Market
(Nasdaq: ABCM).
For more information, please visit www.abcam.com or www.abcamplc.com
Forward-Looking Statements
This announcement contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Any express or implied statements contained in this announcement
that are not statements of historical fact may be deemed to be
forward-looking statements, including, without limitation,
statements regarding Abcam's portfolio and ambitions, expected
performance for 2021, as well as statements that include the words
"expect," "intend," "plan," "believe," "project," "forecast,"
"estimate," "may," "should," "anticipate" and similar statements of
a future or forward-looking nature. Forward-looking statements are
neither promises nor guarantees, but involve known and unknown
risks and uncertainties that could cause actual results to differ
materially from those projected, including, without limitation: a
regional or global health pandemic, including the novel coronavirus
("COVID-19"), which has adversely affected elements of our
business, could severely affect our business, including due to
impacts on our operations and supply chains; challenges in
implementing our strategies for revenue growth in light of
competitive challenges; developing new products and enhancing
existing products, adapting to significant technological change and
responding to the introduction of new products by competitors to
remain competitive; failing to successfully identify or integrate
acquired businesses or assets into our operations or fully
recognize the anticipated benefits of businesses or assets that we
acquire; if our customers discontinue or spend less on research,
development, production or other scientific endeavours; failing to
successfully use, access and maintain information systems and
implement new systems to handle our changing needs; cyber security
risks and any failure to maintain the confidentiality, integrity
and availability of our computer hardware, software and internet
applications and related tools and functions; failing to
successfully manage our current and potential future growth; any
significant interruptions in our operations; if our products fail
to satisfy applicable quality criteria, specifications and
performance standards; failing to maintain our brand and
reputation; our dependence upon management and highly skilled
employees and our ability to attract and retain these highly
skilled employees; and the important factors discussed under the
caption "Risk Factors" in Abcam's prospectus pursuant to Rule
424(b) filed with the U.S. Securities and Exchange Commission
("SEC") on 22 October 2020, which is on file with the SEC and is
available on the SEC website at www.sec.gov, as such factors may be
updated from time to time in Abcam's other filings with the SEC.
Any forward-looking statements contained in this announcement speak
only as of the date hereof and accordingly undue reliance should
not be placed on such statements. Abcam disclaims any obligation or
undertaking to update or revise any forward-looking statements
contained in this announcement, whether as a result of new
information, future events or otherwise, other than to the extent
required by applicable law.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTBRGDBRDDDGDL
(END) Dow Jones Newswires
January 27, 2022 06:59 ET (11:59 GMT)
Abcam (LSE:ABC)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Abcam (LSE:ABC)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
